# Sanara MedTech Inc.: overview SMTI · Nasdaq · CIK 714256 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/smti.md) · [Financials](/companies/smti/financials.md) · [Filings](/companies/smti/filings.md) · [Insiders](/companies/smti/insiders.md) Latest reported revenue: [$28.1m](/filings/0001493152-26-037176.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037176). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [21.7](/filings/0001493152-25-021894.md) | [26.3 d](/filings/0001493152-26-012352.md) | [23.4](/filings/0001493152-26-022479.md) | [25.8](/filings/0001493152-26-037176.md) | [26.3](/filings/0001493152-25-021894.md) | [27.5 d](/filings/0001493152-26-012352.md) | [27.8](/filings/0001493152-26-022479.md) | [28.1](/filings/0001493152-26-037176.md) | | Gross margin | % | [90.8%](/filings/0001493152-25-021894.md) | [91.4% d](/filings/0001493152-26-012352.md) | [92.2%](/filings/0001493152-26-022479.md) | [92.5%](/filings/0001493152-26-037176.md) | [92.9%](/filings/0001493152-25-021894.md) | [93.2% d](/filings/0001493152-26-012352.md) | [93.1%](/filings/0001493152-26-022479.md) | [93.0%](/filings/0001493152-26-037176.md) | | Operating margin | % | [3.6%](/filings/0001493152-25-021894.md) | [8.6% d](/filings/0001493152-26-012352.md) | [3.5%](/filings/0001493152-26-022479.md) | [9.6%](/filings/0001493152-26-037176.md) | [11.2%](/filings/0001493152-25-021894.md) | [3.8% d](/filings/0001493152-26-012352.md) | [9.5%](/filings/0001493152-26-022479.md) | [6.3%](/filings/0001493152-26-037176.md) | | Net margin | % | [(13.2%)](/filings/0001493152-25-021894.md) | [(5.8%) d](/filings/0001493152-26-012352.md) | [(15.1%)](/filings/0001493152-26-022479.md) | [(7.8%)](/filings/0001493152-26-037176.md) | [(115.5%)](/filings/0001493152-25-021894.md) | [(5.8%) d](/filings/0001493152-26-012352.md) | [1.7%](/filings/0001493152-26-022479.md) | [(1.6%)](/filings/0001493152-26-037176.md) | | Diluted EPS | $ per share | [(0.34)](/filings/0001493152-25-021894.md) | not reported | [(0.41)](/filings/0001493152-26-022479.md) | [(0.23)](/filings/0001493152-26-037176.md) | [(3.40)](/filings/0001493152-25-021894.md) | not reported | [0.05](/filings/0001493152-26-022479.md) | [(0.05)](/filings/0001493152-26-037176.md) | | Free cash flow | $m | [2.0 d](/filings/0001493152-25-021894.md) | [0.9 d](/filings/0001493152-26-012352.md) | [(3.7)](/filings/0001493152-26-022479.md) | [0.9 d](/filings/0001493152-26-037176.md) | [1.1 d](/filings/0001493152-25-021894.md) | [3.9 d](/filings/0001493152-26-012352.md) | [(2.5)](/filings/0001493152-26-022479.md) | [2.0 d](/filings/0001493152-26-037176.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [24.1](/filings/0001493152-23-008240.md) | [45.8](/filings/0001493152-24-011128.md) | [65.0](/filings/0001641172-25-000632.md) | [86.7](/filings/0001493152-26-012352.md) | [103](/filings/0001493152-26-012352.md) | | Gross margin | % | [90.4%](/filings/0001493152-23-008240.md) | [86.1%](/filings/0001493152-24-011128.md) | [87.9%](/filings/0001641172-25-000632.md) | [90.6%](/filings/0001493152-26-012352.md) | [92.7%](/filings/0001493152-26-012352.md) | | Operating margin | % | [(30.6%)](/filings/0001493152-23-008240.md) | [(27.3%)](/filings/0001493152-24-011128.md) | [(6.5%)](/filings/0001641172-25-000632.md) | [1.5%](/filings/0001493152-26-012352.md) | [7.1%](/filings/0001493152-26-012352.md) | | Net margin | % | [(32.8%)](/filings/0001493152-23-008240.md) | [(17.3%)](/filings/0001493152-24-011128.md) | [(6.6%)](/filings/0001641172-25-000632.md) | [(11.2%)](/filings/0001493152-26-012352.md) | [(36.4%)](/filings/0001493152-26-012352.md) | | Diluted EPS | $ per share | [(1.08)](/filings/0001493152-22-008222.md) | [(1.00)](/filings/0001493152-24-011128.md) | [(0.52)](/filings/0001641172-25-000632.md) | [(1.14)](/filings/0001493152-26-012352.md) | [(4.36)](/filings/0001493152-26-012352.md) | | Free cash flow | $m | [(5.0)](/filings/0001493152-23-008240.md) | [(5.7)](/filings/0001493152-24-011128.md) | [(3.5)](/filings/0001641172-25-000632.md) | [(0.2)](/filings/0001493152-26-012352.md) | [2.2](/filings/0001493152-26-012352.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/smti/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.9m | 248,827 | | Added +20,060 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.6m | 194,897 | | Added +43,530 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $3.1m | 130,995 | | Reduced −394 | | [Stonebridge Wealth Management, LLC](/funds/2082460.md) | 2026-06-30 | $3.1m | 129,452 | | Reduced −7,447 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $2.6m | 112,207 | | Added +72,269 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.1m | 89,179 | | Added +3,517 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.8m | 74,198 | | Added +52,613 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.6m | 67,400 | | Added +2,720 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.5m | 63,469 | | Added +780 | | [Squarepoint Ops LLC](/funds/1642575.md) | 2026-06-30 | $1.3m | 53,811 | | Reduced −19,796 | ## Recent filings [All 593 filings](/companies/smti/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:15 ET | [8-K](/filings/0001493152-26-049275.md) | 7.01 Regulation FD disclosure | 0001493152-26-049275 | | 2026-10-16 | 09:20 ET | [8-K](/filings/0001213900-26-110053.md) | 8.01 Other events | 0001213900-26-110053 | | 2026-10-01 | 19:48 ET | [8-K](/filings/0001213900-26-105390.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001213900-26-105390 | | 2026-08-11 | 17:08 ET | [10-Q](/filings/0001493152-26-037176.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037176 | | 2026-08-11 | 16:10 ET | [8-K](/filings/0001493152-26-037131.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037131 | | 2026-08-11 | 16:05 ET | [8-K/A](/filings/0001493152-26-037112.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037112 | | 2026-07-29 | 16:21 ET | [8-K](/filings/0001493152-26-035196.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035196 | | 2026-06-09 | 16:15 ET | [8-K](/filings/0001493152-26-027936.md) | 5.07 Shareholder vote results | 0001493152-26-027936 | | 2026-06-04 | 16:15 ET | [8-K](/filings/0001493152-26-027274.md) | 1.02 Termination of a material agreement | 0001493152-26-027274 | | 2026-05-12 | 16:03 ET | [10-Q](/filings/0001493152-26-022479.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022479 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012352.md), filed Mar 24, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/07361755-d298-41a6-b15f-d7aaaf89a242) ## About the filer - CIK: 714256 - Tickers: SMTI - Exchange: Nasdaq - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: TX - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:18 ET. No prices; not investment advice.